MedTrace Logo

Slovenian National COVID-19 Prevalence Study

NCT04376996 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2021-10-06

No results posted yet for this study

Summary

The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that were randomly selected from the Slovenian population. The sample is representative in age, gender, and geographical distribution.

The main objective is to assess how many people in Slovenia have COVID-19 in April/May 2020 and how many were infected with SARS-CoV-2 previously.

The investigators are using a direct detection of SARS-CoV-2 RNA in nasopharyngeal samples with validated two-target PCR-based commercial assay. For a serological response to the etiological agent, IgG and IgA anti-SARS-CoV-2 antibodies are measured in plasma samples using a validated commercial assay.

Conditions

Interventions

DIAGNOSTIC_TEST

NO intervention planned due to the observational study design - only a diagnostic testing

Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood

Sponsors & Collaborators

  • University of Ljubljana

    lead OTHER

Principal Investigators

  • Mario Poljak, MD · Univesity of Ljubljana, Slovenia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2020-11-15
Completion
2020-12-15

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04376996 on ClinicalTrials.gov